| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...
 
																	
 
																	TD Cowen analyst Joseph Thome initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Pric...
 
																	
 
																	JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...
 
																	 
																	Stifel analyst Dae Gon Ha reinstates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and announces $89 price target.
